Anna D. Staniszewska

1.8k total citations
30 papers, 984 citations indexed

About

Anna D. Staniszewska is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anna D. Staniszewska has authored 30 papers receiving a total of 984 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anna D. Staniszewska's work include PARP inhibition in cancer therapy (10 papers), DNA Repair Mechanisms (9 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Anna D. Staniszewska is often cited by papers focused on PARP inhibition in cancer therapy (10 papers), DNA Repair Mechanisms (9 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Anna D. Staniszewska collaborates with scholars based in United Kingdom, United States and Singapore. Anna D. Staniszewska's co-authors include Valeria Poli, Christine J. Watson, Richard Clarkson, Wenjing Li, Blandine Kedjouar, Nader Omidvar, James Turkson, Peter Kreuzaler, Richard A. Flavell and Larissa S. Carnevalli and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Nature Cell Biology.

In The Last Decade

Anna D. Staniszewska

28 papers receiving 965 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna D. Staniszewska United Kingdom	12	486	462	248	206	172	30	984
Miriam Redrado Spain	20	544 1.1×	518 1.1×	177 0.7×	233 1.1×	270 1.6×	39	1.1k
Anne Keating United States	13	638 1.3×	409 0.9×	192 0.8×	130 0.6×	115 0.7×	26	899
Suresh Veeramani United States	15	521 1.1×	254 0.5×	314 1.3×	272 1.3×	147 0.9×	23	1.0k
Stacey M. Bagby United States	21	568 1.2×	516 1.1×	158 0.6×	194 0.9×	242 1.4×	62	1.1k
Anne Fassl Germany	15	579 1.2×	323 0.7×	206 0.8×	94 0.5×	253 1.5×	22	921
Jonathan F. Anker United States	14	617 1.3×	519 1.1×	227 0.9×	233 1.1×	251 1.5×	31	1.1k
Eric C. McGary United States	15	628 1.3×	480 1.0×	143 0.6×	134 0.7×	205 1.2×	22	1.1k
Samuel W. Brady United States	14	608 1.3×	588 1.3×	188 0.8×	93 0.5×	187 1.1×	25	1.1k
Julia V. Burnier Canada	21	592 1.2×	408 0.9×	123 0.5×	174 0.8×	318 1.8×	73	1.2k
Renaud Grépin France	16	601 1.2×	278 0.6×	154 0.6×	150 0.7×	278 1.6×	26	917

Countries citing papers authored by Anna D. Staniszewska

Since Specialization

Citations

This map shows the geographic impact of Anna D. Staniszewska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna D. Staniszewska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna D. Staniszewska more than expected).

Fields of papers citing papers by Anna D. Staniszewska

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna D. Staniszewska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna D. Staniszewska. The network helps show where Anna D. Staniszewska may publish in the future.

Co-authorship network of co-authors of Anna D. Staniszewska

This figure shows the co-authorship network connecting the top 25 collaborators of Anna D. Staniszewska. A scholar is included among the top collaborators of Anna D. Staniszewska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna D. Staniszewska. Anna D. Staniszewska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Illuzzi, Giuditta, Alessandro Galbiati, Anna D. Staniszewska, et al.. (2025). Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair. NAR Cancer. 7(4). zcaf035–zcaf035.

Cuesta, Natalia, et al.. (2025). NF-κB-Inducing Kinase Is Essential for Effective c-Rel Transactivation and Binding to the Il12b Promoter in Macrophages. Biology. 14(1). 33–33.

Decio, Alessandra, Mark R. Albertella, Joanne Wilson, et al.. (2023). The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin. Cancer Research Communications. 3(3). 489–500. 9 indexed citations

Hodson, David, Hitesh Mistry, James Yates, et al.. (2023). Radiation in Combination with Immune Checkpoint Blockade and DNA Damage Response Inhibitors in Mice: Dosage Optimization in MC38 Syngeneic Tumors via Modelling and Simulation. Journal of Pharmacology and Experimental Therapeutics. 387(1). 44–54. 2 indexed citations

Hodson, David, Hitesh Mistry, Michael Davies, et al.. (2023). Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of theDNAdamage response pathway. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1640–1652. 5 indexed citations

Staniszewska, Anna D., Joshua Armenia, Matthew King, et al.. (2022). PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. OncoImmunology. 11(1). 2083755–2083755. 37 indexed citations

Staniszewska, Anna D., Domenic Pilger, Giuditta Illuzzi, et al.. (2022). DDDR-01. AZD9574 IS A NOVEL, BRAIN PENETRANT PARP-1 SELECTIVE INHIBITOR WITH ACTIVITY IN AN INTRACRANIAL XENOGRAFT MODEL OF TRIPLE NEGATIVE BREAST CARCINOMA WITH HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY. Neuro-Oncology. 24(Supplement_7). vii98–vii98. 2 indexed citations

Decio, Alessandra, et al.. (2021). Abstract P217: The next generation PARP inhibitor AZD5305 is active in a broad range of pre-clinical models of ovarian cancer. Molecular Cancer Therapeutics. 20(12_Supplement). P217–P217. 1 indexed citations

Staniszewska, Anna D., Michalina Kazek, Mirosława Koronkiewicz, et al.. (2020). Antifungal polybrominated proxyphylline derivative induces Candida albicans calcineurin stress response in Galleria mellonella. Bioorganic & Medicinal Chemistry Letters. 30(23). 127545–127545. 3 indexed citations

10.

Ward, Richard A., Ambra Bianco, Nicola Colclough, et al.. (2019). Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR). Cancer Research. 79(13_Supplement). 4813–4813. 1 indexed citations

11.

Taylor, Molly A., Adina Hughes, Josephine Walton, et al.. (2019). Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. Journal for ImmunoTherapy of Cancer. 7(1). 328–328. 70 indexed citations

12.

Michaloglou, Chrysiis, Claire Crafter, Rasmus Siersbæk, et al.. (2018). Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer. Molecular Cancer Therapeutics. 17(5). 908–920. 128 indexed citations

13.

Floc’h, Nicolas, Matthew J. Martin, Jonathan W. Riess, et al.. (2018). Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Molecular Cancer Therapeutics. 17(5). 885–896. 85 indexed citations

14.

Langdon, Sophie, Adina Hughes, Molly A. Taylor, et al.. (2018). Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. OncoImmunology. 7(8). e1458810–e1458810. 40 indexed citations

15.

Lynch, James T., Urszula M. Polanska, Oona Delpuech, et al.. (2017). Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clinical Cancer Research. 23(24). 7584–7595. 24 indexed citations

16.

Ross, Sarah J., Alexey S. Revenko, Lyndsey Hanson, et al.. (2017). Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Science Translational Medicine. 9(394). 143 indexed citations

17.

Riess, Jonathan W., Nicolas Floc’h, Matthew W. Martin, et al.. (2017). Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.. Journal of Clinical Oncology. 35(15_suppl). 9030–9030. 5 indexed citations

18.

Staniszewska, Anna D., Sara Pensa, María M. Caffarel, et al.. (2012). Stat3 Is Required to Maintain the Full Differentiation Potential of Mammary Stem Cells and the Proliferative Potential of Mammary Luminal Progenitors. PLoS ONE. 7(12). e52608–e52608. 19 indexed citations

19.

Kreuzaler, Peter, Anna D. Staniszewska, Wenjing Li, et al.. (2011). Stat3 controls lysosomal-mediated cell death in vivo. Nature Cell Biology. 13(3). 303–309. 246 indexed citations

20.

Vos, Mariska, Anna D. Staniszewska, Jörg Hamann, et al.. (2010). CD70-Driven Chronic Immune Activation Is Protective against Atherosclerosis. Journal of Innate Immunity. 2(4). 344–352. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact